REPUBLIC OF SLOVENIA
MINISTRY OF HEALTH
AGENCY FOR MEDICINAL PRODUCTS AND MEDICAL DEVICES

EU APPROVAL OF CANCER MEDICINES

"United against Cancer"

ECPC

CEE Cancer Patient Summit

Ljubljana, SLOVENIA

November 2006

REPUBLIC OF SLOVENIA
MINISTRY OF HEALTH
AGENCY FOR MEDICINAL PRODUCTS AND MEDICAL DEVICES

Assoc.Prof. **Stanislav Primožič**, Ph.D., M.Pharm.
DIRECTOR

With tributes to:

Dr. **Vesna Koblar**
Head, Regulatory Sector – Medicinal Products
and Medical devices for Human Use

Four steps

of entry of a medicinal product to a national market

DRA

Q,E,S

pricing

controlled /
free market

reimbursement

3rd party
payor / user

procurement

public /
institutional

Systemic players:

Transnational

EU/EC-DGs/EUDRA/G10
EMEA
WTO
WHO
Professional Organizations
Pharmaceutical Companies

National

Gatekeepers
Ministries
Regulatory Agencies

Local Rep's
Ibid.

HMA

AIMS of EU DRA

- HIGH LEVEL OF PUBLIC HEALTH
- HIGH LEVEL OF COMPETITIVENESS OF PHARMACEUTICAL INDUSTRY
- ENLARGEMENT REQUIREMENTS

DRUG REGULATORY AUTHORITIES IN THE EU

- CORE STRUCTURES:
  - CENTRAL AGENCY:
    - EMEA: European Medicines Agency
      - MB, CXMP, PhVWP, **SAG**
  - NATIONAL DRAs
    - MHRA (UK), AFSSAPS (F), BfArM (D), ARSZMP (SLO), ...
  - Functional connections:
    - HMA, CMD(h), CMD(v), TIGs…

- SUPPORTIVE STRUCTURES
  - EDQM / European Pharmacopoeia
  - OMCL Network
  - PIC

NETWORKING
Why work-share is the future?

- Regulation of medicines in Europe is a shared task between EU bodies and NCAs
- NCAs knowledge and resources are pivotal in this process
- Resources are limited – co-operation is key to progress
- ”Best excellence” – NCAs and EMEA in united front
- Benchmarking

COMPOSITION OF SAGs

	Academic Hospital	National Institute	Regulatory
Antiinfectives	5	3	-
CNS	7	-	-
Diabetes/Endo	7	2	1
Diagnostics	7	-	-
HIV/Antivirals	5	2	1
Oncology	6	3	-
Cardiovascular	6	3	-
	43	13	2

Source:EMEA

HMA Strategy Paper

(http://heads.medagencies.org/heads/hoa_docs.html)

Areas of activity:

- Communication and Information
- Scientific Assessment Process
- Inspection, Laboratory Control and Enforcement
- Scientific Resources
- Pharmacovigilance
- IT Information Systems

EU and NATIONAL LEGISLATION

ZZdr-1 (SI) Specific modifications linked to **EU** requirements:

- Introducing of new and updated definitions (generic medicines, biological medicines…)
- Consolidation of procedures (quick, transparent…)
- Improvement of legal basis for co-operation between EU Member States
- Strengthening of pharmacovigilance
- Introducing specific incentives for industry (new data exclusivity period - 8+2+1

NATIONAL LEGISLATION: ZZdr-1 (SI)

Specific modifications linked to **national** requirements:

- Better inclusion of provisions on drug pricing, that include the concept of interchangeability of medicinal product
- Retail sale of medicinal products through internet
- Retail sale of OTC medicinal products in pharmacies and specialized shops

OBLIGATORY CENTRALISED PROCEDURE



EMEA CP: Mandatory Scope

Art. 3(1) of Regulation (EC) No 726/2004 & its Annex		
Indent 1	**Indent 3**	**Indent 4**
"Biotech" MPs -Recombinant DNA technology Controlled gene expression Monoclonal AB	Mandatory therapeutic Classes" •AIDs •Cancer •Neurodeg. disorders •Diabetes	Orphan MPs

Source: EMEA

EMEA ACCELERATED ASSESSMENT PROCEDURE

- Purpose: to meet the legitimate expectations of patients and to take into account increasingly rapid progress of science and therapies

- Article 14(9) of Regulation (EC) 726/2004
  - **Major interest** from the point of view of **public health** and in particular from the viewpoint of **therapeutic innovation**
  - **Scientific opinion in 150 days** (instead of 210)

Source: EMEA

OPTIONAL CENTRALISED PROCEDURE

FROM 20.NOV.05, NAS:

- NOT AUTHORISED IN THE EU
- COMMUNITY INTEREST

BY 20.NOV.05
LIST B: CR 2309/93/EEC

-GENERICS OF CENTRALLY
-AUTHORISED PRODUCTS

MRP vs DP


SUBMISSION
RMS
210
AR
MA
SUBMISSION
+
AR
CMS
CMS
CMS
90
...
MA
MA
MA
...
120
90
SUBMISSION
RMS
CMS
CMS
CMS
...
DRAFT AR
AR
MA
MA
MA
MA
...

Positive COMP opinions in 2004



Source: EMEA

LABELLING AND PIL

- SECTIONS DEFINED BY DIRECTIVE 2001/83/EC:
- PIL AND OUTER PACKAGING SHALL REFLECT THE RESULTS OF CONSULTATIONS WITH TARGET PATIENT GROUPS THAT IT IS LEGIBLE, CLEAR AND EASY TO USE
- BRAILLE

PharmacoVigilance

- STRENGTHENING OF PhV
- ASSESSMENT OF SAFETY
- POSITIVE ASSESSMENT OF THE RISK/BENEFIT RATIO
- RISK MANAGEMENT SYSTEM

PSUR

- 2X/Yr AFTER GRANTING THE MA AND UNTIL THE PLACING ON THE MARKET
- 2X/Yr, FIRST 2Yrs AFTER GRANTING MA
- 1X/Yr, NEXT 2Yrs
- 1X/3 Yrs, WITHIN THE PERIOD OF VALIDITY OF MA
- UPON ON REQUEST OF CA

TRANSPARENCY

- **PUBLICLY ACCESSIBLE INFORMATION**

  (NO COMMERCIALLY SENSITIVE INFORMATION SHOULD BE INCLUDED):

  - DECLARATION ON NO CONFLICT OF INTEREST FOR CA STAFF AND EXPERTS
  - AR
  - RULES OF PROCEDURES, AGENDAS OF MEETINGS, RECORDS, DECISION TAKEN
  - JUSTIFICATIONS FOR REFUSAL OF MA
  - PhV DATA THAT CONCERN PUBLIC HEALTH
  - EUROPHARM DATABASE – PARTIALLY AVAILABLE TO THE PUBLIC

Figure 1.3 Price index for medicines 2003 (Denmark=100)



Source: Jörgensen KP og Keiding H. Danske og Udenlandske medicinpriser 2003, Köpenhavn, 2004.

* Approximate level of SI max price level entered to original picture by ARSZMP


Wholesale Prices of Medicinal Products (SLO) - april 2005
Centralized
National
500000
450000
400000
350000
300000
250000
200000
150000
100000
50000
0
Sl Tolar
A
B
C
D
G
H
J
L
M
N
P
R
S
V
mean in ATC level 1 (anatomic/therapeutic groups)

PRICES OF MEDICINAL PRODUCTS SLOVENIA Oct 2006

	ATC1 L [CP]	ALL MPs
N	75	2973
MEAN	970,57	77,03
SD	1401,18	243,27
MEDIAN	606,56	14,63
MAX	10521,54	4054,19
MIN	35,38	0,44

Pharmaceutical Forum



Principles

- Broad participation
- Highest level political participation + technical preparation
- Collaboration, facilitated by EC
- Open set-up, all issues and proposals can be considered

Source: European Commission

Ph. Forum WG Pricing

Multiple expectations and regulations

- Need to balance expectations on pricing from Member States/payors, patients and industry
- National competence
- Decision-process needs to be in line with Dir 89/105/EEC (timing, criteria, publications)

Working Group on Pricing

- Share and examine experiences with different P+R mechanisms and cost-containment strategies on
  - Impact on **cost**
  - **Access** to market
  - **Reward** for innovation
- Consider impact of cross-national mechanisms (parallel trade, int'l reference pricing)
- Aim for a long-term perspective for both Member States and Industry

Source: European Commission

Ph. Forum WG Info to Patients

Need to improve information to patients but how?

- Legislation on information drafted before the Internet
- No clear distinction between information & advertising
- Factors to consider
  - Increasing pressure on national healthcare budgets
  - Potential role of industry
  - Growing demands from patients for more & better info

Working Group on Patient Information

- Examine options to
  - Provide information to patients in their own language, considering different factors
  - Put medicine information into a broader context
  - Build a central EU information tool
- Build on existing expertise and take account of existing initiatives (e.g., EuroPharm Database (EMEA)

Source: European Commission

The System

Pharmacy

Gov't
+
EC
+
DRAs

Health Insurance

M.P.



the patient

the prescriber

The Media

pharma industry